BLAINTRAVENOUSSOLUTION
Approved
Oct 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
Albumin (Human) (albumin human) by Octapharma is glycoprotein. Approved for burn injury. First approved in 2006.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Albumin (Human) is a human serum albumin solution administered intravenously to restore intravascular oncotic pressure and plasma volume in burn injury patients. It functions as a hyperoncotic plasma expander that accounts for 75% of normal oncotic pressure within the intravascular space. The drug binds and transports multiple molecules while providing hemostatic and free radical scavenging effects.
$0.013BPart D
LOE ApproachingThis mature biologic asset has limited Part D penetration and faces approaching loss of exclusivity, signaling a small, stable team focused on maintaining market position rather than expansion.
Mechanism of Action
glycoprotein. It has the lowest molecular weight (66,241 Daltons) of all plasma proteins. Because of its three dimensional structure, solutions of albumin have a lower viscosity than solutions of other plasma proteins. This is important since work performed by the heart depends in part on the…
Pharmacologic Class:
Human Serum Albumin
Indications (1)
Worked on Albumin (Human) at Octapharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.